Loading
A phase 3 trial of Nivolumab in hepatocellular carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation is a phase 3 interventional study registered as NCT03383458 by Bristol-Myers Squibb, with 545 participants enrolled, started 2018-04-18 and due to reach its primary completion in 2026-05-27. Interventions recorded: Nivolumab, Placebo. Conditions listed: Hepatocellular Carcinoma, Liver Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Early hepatocellular carcinoma (BCLC 0 and A), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/